Athenex Inc chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share 1.04
Dividend & YieldN/A$ (N/A)
Beta 1.1
Market capitalization 27.14M
Operating cash flow -97.95M
ESG Scores unknown

Company description

Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral paclitaxel and encequidar, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in cutaneous angiosarcoma, advanced gastric cancer, and advanced solid malignancies. It also offers Src Kinase product candidates comprising Tirbanibulin ointments for actinic keratosis, skin cancers, and psoriasis. In addition, the company is developing KUR-501, an autologous product that is in a phase I clinical trial for treating children with relapsed-refractory (R/R) high risk neuroblastoma; KUR-502, an allogeneic product, which is in a phase I clinical trial for treating adults with R/R CD19 positive malignancies, including B cell lymphoma, acute lymphoblastic leukemia, and chronic lymphocytic leukemia; and KUR-503, an allogeneic product that is in preclinical development for advanced hepatocellular carcinomas, as well as TCRT-ESO-A2, an autologous T cell receptor (TCR)-T cell therapy that is in phase 1 clinical trial for solid tumors. Further, it is developing dual absorption enhancers to inhibit the P-gp transporter and the cytochrome p450 3A enzymes within the gastrointestinal tract; and has a portfolio of TCRs that recognize hotspot mutations in p53, KRAS, and EGFR genes for multiple tumors. The company was formerly known as Kinex Pharmaceuticals LLC and changed its name to Athenex, Inc. in August 2015. Athenex, Inc. was incorporated in 2003 and is headquartered in Buffalo, New York.

Sector: Healthcare - Industry: Drug Manufacturers—Specialty & Generic

Financial Ratios
Quick Ratio1.03
Working Capital-5.35
Return On Equity-3.91
Debt To Equity2.02
Fixed Asset Ratio0.42
Fixed Interest Cover-5.54

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities 3.53M 19.34M -13.71M -19.22M
Total Cashflows From Investing Activities -48.96M 7.5M -118.97M 104.98M
Net Borrowings 49.46M 5.49M 90.81M -203k
Total Cash From Financing Activities 169.03M 167.45M 209.43M 2.46M
Change To Operating Activities -13.97M 864k 5.88M 4.06M
Issuance Of Stock 127.09M 163.06M 128.7M 2.92M
Net Income -117.44M -123.75M -146.18M -199.77M
Change In Cash 10.51M 77.88M -41.59M -34.38M
Effect Of Exchange Rate -175k 389k -799k 548k
Total Cash From Operating Activities -109.39M -97.46M -131.24M -142.38M
Depreciation 3.27M 3.81M 4.46M 4.68M
Change To Account Receivables -4.48M -3.74M -16.43M -2.7M
Other Cashflows From Financing Activities -7.51M -1.1M -10.09M -178k
Change To Netincome 31.42M 8.83M 29.17M 72.89M
Capital Expenditures -3.32M -9.71M -8.62M -8.4M

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development 119.61M 84.39M 75.9M 80.2M
Income Before Tax -128.61M -124.12M -140.35M -204.91M
Net Income -117.44M -123.75M -146.18M -199.77M
Selling General Administrative 49.01M 66.26M 92.86M 72.55M
Gross Profit 42.09M 31.61M 49.04M 37.77M
Ebit -126.52M -119.04M -119.73M -114.97M
Operating Income -126.52M -119.04M -119.73M -114.97M
Interest Expense -3.58M -6.95M -11.22M -20.74M
Income Tax Expense 100k 928k 4.09M -10.6M
Total Revenue 89.1M 101.23M 144.39M 120.18M
Cost Of Revenue 47.01M 69.62M 95.36M 82.41M
Total Other Income ExpenseNet -2.09M -5.07M -20.62M -89.93M
Net Income From Continuing Ops -128.71M -125.04M -144.44M -194.31M
Net Income Applicable To Common Shares -117.44M -123.75M -146.18M -199.77M

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 102.33M 134.08M 218.98M 233M
Total Stockholder Equity 139.35M 188.22M 179.78M 51.13M
Other Current Liabilities 16.63M 23.22M 7.85M 10.16M
Total Assets 231.09M 309.93M 384.33M 267.45M
Common Stock 69k 83k 95k 111k
Other Current Assets 21.28M 17.78M
Retained Earnings -443.72M -567.47M -713.64M -913.41M
Treasury Stock -8.06M -8.04M -8.54M -7.97M
Cash 49.79M 127.67M 69.59M 35.2M
Total Current Liabilities 51.68M 71.53M 62.14M 96.05M
Other Stockholder Equity -656k -635k -1.13M -487k
Property, Plant, and Equipment 11.45M 31.97M 31.73M 34.22M
Total Current Assets 170.82M 230.93M 291.96M 133.4M
Net Tangible Assets 91.01M 141.19M 130.67M -20.77M
Net Receivables 12.95M 16.69M 23.6M 26.64M
Accounts Payable 13M 23.33M 18.42M 16.74M


Insider Transactions

Here are the insider transactions of stock shares related to Athenex Inc:

Filer Name Transaction Text Ownership Date Filer Relation Shares
LAU JOHNSON YIU NAMStock Award(Grant) at price 0.19 per share.D2022-11-18Chief Executive Officer58.76k
KWAN RUDOLFStock Award(Grant) at price 0.19 per share.D2022-11-18Officer25.26k
COOK TIMOTHY DEVEREStock Award(Grant) at price 0.19 per share.D2022-11-18Officer2.58k
LAU JOHNSON YIU NAMStock Award(Grant) at price 0.20 per share.D2022-11-04Chief Executive Officer58.4k
KWAN RUDOLFStock Award(Grant) at price 0.20 per share.D2022-11-04Officer25.1k
COOK TIMOTHY DEVEREStock Award(Grant) at price 0.20 per share.D2022-11-04Officer2.56k
LAU JOHNSON YIU NAMStock Award(Grant) at price 0.18 per share.D2022-10-21Chief Executive Officer62.64k
KWAN RUDOLFStock Award(Grant) at price 0.18 per share.D2022-10-21Officer26.92k
COOK TIMOTHY DEVEREStock Award(Grant) at price 0.18 per share.D2022-10-21Officer2.75k
LAU JOHNSON YIU NAMStock Award(Grant) at price 0.24 per share.D2022-10-07Chief Executive Officer47.32k
VIERLING JOHN MOOREStock Award(Grant) at price 0.24 per share.D2022-10-07Director35.28k
TSANG BENSON KWAN HUNGStock Award(Grant) at price 0.24 per share.D2022-10-07Director47.74k
SPIEGEL ROBERT JStock Award(Grant) at price 0.24 per share.D2022-10-07Director12.45k
WU JINNStock Award(Grant) at price 0.24 per share.D2022-10-07Director35.28k
KWAN RUDOLFStock Award(Grant) at price 0.24 per share.D2022-10-07Officer20.34k
FOK MANSONStock Award(Grant) at price 0.24 per share.D2022-10-07Director31.13k
DAVIS STEPHANIE AStock Award(Grant) at price 0.24 per share.D2022-10-07Director19.72k
COOK TIMOTHY DEVEREStock Award(Grant) at price 0.24 per share.D2022-10-07Officer2.08k
LAU JOHNSON YIU NAMStock Award(Grant) at price 0.24 per share.D2022-09-23Chief Executive Officer47.3k
KWAN RUDOLFStock Award(Grant) at price 0.24 per share.D2022-09-23Officer20.33k
COOK TIMOTHY DEVEREStock Award(Grant) at price 0.24 per share.D2022-09-23Officer2.08k
LANG DANIEL M.D.D2022-09-16Officer12.5k
COOK TIMOTHY DEVERED2022-09-16Officer2.25k
LAU JOHNSON YIU NAMStock Award(Grant) at price 0.46 per share.D2022-09-09Chief Executive Officer24.6k
KWAN RUDOLFStock Award(Grant) at price 0.46 per share.D2022-09-09Officer10.57k
COOK TIMOTHY DEVEREStock Award(Grant) at price 0.46 per share.D2022-09-09Officer1.08k
LAU JOHNSON YIU NAMStock Award(Grant) at price 0.47 per share.D2022-08-26Chief Executive Officer24.07k
KWAN RUDOLFStock Award(Grant) at price 0.47 per share.D2022-08-26Officer10.35k
COOK TIMOTHY DEVEREStock Award(Grant) at price 0.47 per share.D2022-08-26Officer1.06k
WU JINNPurchase at price 0.42 per share.D2022-08-22Director10k
LAU JOHNSON YIU NAMPurchase at price 0.45 per share.D2022-08-19Chief Executive Officer20k
LAU JOHNSON YIU NAMStock Award(Grant) at price 0.52 per share.D2022-08-12Chief Executive Officer21.92k
KWAN RUDOLFStock Award(Grant) at price 0.52 per share.D2022-08-12Officer9.42k
COOK TIMOTHY DEVEREStock Award(Grant) at price 0.52 per share.D2022-08-12Officer961
YORDON JEFFREY MD2022-08-03Officer12.5k
LAU JOHNSON YIU NAMD2022-08-03Chief Executive Officer37.5k
VIERLING JOHN MOORED2022-08-03Director7.5k
TSANG BENSON KWAN HUNGD2022-08-03Director10k
SPIEGEL ROBERT JD2022-08-03Director8.75k
WU JINND2022-08-03Director7.5k
KWAN RUDOLFD2022-08-03Officer17.5k
FOK MANSOND2022-08-03Director6.25k
KANFER JORDAN S.D2022-08-03Director7.5k
DAVIS STEPHANIE AD2022-08-03Director8.75k
LAU JOHNSON YIU NAMStock Award(Grant) at price 0.51 per share.D2022-07-29Chief Executive Officer22.48k
COOK TIMOTHY DEVEREStock Award(Grant) at price 0.51 per share.D2022-07-29Officer986
VIERLING JOHN MOOREStock Award(Grant) at price 0.67 per share.D2022-07-20Director12.77k
TSANG BENSON KWAN HUNGStock Award(Grant) at price 0.67 per share.D2022-07-20Director17.28k
SPIEGEL ROBERT JStock Award(Grant) at price 0.67 per share.D2022-07-20Director4.51k
WU JINNStock Award(Grant) at price 0.67 per share.D2022-07-20Director12.77k
FOK MANSONStock Award(Grant) at price 0.67 per share.D2022-07-20Director11.27k

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to Athenex Inc. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on Athenex Inc

Here is the result of two systematic investment strategies applied to Athenex Inc. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on Athenex Inc

The following chart shows the equity curve of the two systematic investment strategies applied to Athenex Inc:

Athenex Inc automated entries

The systematic investment strategy that buys the first day of the month would give a performance of -82.11% on the backtest period.

Performance at glance

Performance

-82.11 %

Latent gain

-1449.57 $

Invested capital

1765.47 $

Annualized return

-20.03 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on Athenex Inc

This is the result of two momentum investment strategies applied to Athenex Inc. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on Athenex Inc

The following chart shows all the entries opened by the momentum investment system on Athenex Inc:

Athenex Inc momentum entries
  • The first momentum investment strategy would give -75.1% of return on Athenex Inc. That represents -3950.31$ of latent gain with 5260.08$ of employed capital.
  • The second momentum investment strategy would give -77.74% of return on Athenex Inc. That represents -2919.35$ of latent gain with 3755.27$ of employed capital.
Performance at glance (1Q Momentum)

Performance

-75.1 %

Latent gain

-3950.31 $

Invested capital

5260.08 $

Annualized return

0.0 %
Performance at glance (2Q Momentum)

Performance

-77.74 %

Latent gain

-2919.35 $

Invested capital

3755.27 $

Annualized return

-21.48 %

Momentum equity curve on Athenex Inc

The following chart shows the equity curve of the two momentum strategies applied to Athenex Inc:

Athenex Inc momentum equity

Note: the dividends potentially given by Athenex Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Athenex Inc

The following chart shows the employed capital evolution of the two momentum strategies on Athenex Inc since the beginning:

Athenex Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Buy the dip strategy result on Athenex Inc

Buy the dip entry openings on Athenex Inc

Athenex Inc

The performance achieved by the robo-advisor on Athenex Inc is 0%. That represents 0.0$ of latent gain with 0.0$ of employed capital. The following chart shows Athenex Inc stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of Athenex Inc, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

0 %

Latent gain

0.0 $

Invested capital

0.0 $

Annualized return

0.0 %

Equity curve of the strategy applied to Athenex Inc

The following chart shows the result of the investment strategy applied to Athenex Inc:

Athenex Inc

Note: the dividends potentially given by Athenex Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Athenex Inc

The following chart shows the employed capital evolution since the beginning of the investment strategy on Athenex Inc:

Athenex Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on Athenex Inc

In this section, I will compare the three previous investment strategies applied to Athenex Inc.

Equity curve comparison on Athenex Inc

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

Athenex Inc investment strategy comparison

Employed capital comparison on Athenex Inc

Athenex Inc investment comparison

Performance comparison on Athenex Inc

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment -82.11% -1449.57$ 1765.47$ -20.03%
Momentum 1 quarter -75.1% -3950.31$ 5260.08$ -19.46%
Momentum 2 quarters -77.74% -2919.35$ 3755.27$ -21.48%
Non-directional 0% 0.0$ 0.0$ 0.0%
Annualized return comparison

Automatic investment

-20.03 %

Momentum 1Q

-21.48 %

Momentum 2Q

-21.48 %

Non-directional

0.0 %

Correlated stocks

Here are the most positively and negatively correlated stocks with Athenex Inc:

Note: The algorithm computes the probability of correlation between Athenex Inc and the other stocks. There may be false positives or some missing correlated stocks. If the price of Athenex Inc does not vary for 36 weeks, the correlation calculation result will be wrong.


Company information

Company name Athenex Inc
Country United States
City Buffalo
Address Conventus Building
Phone 716 427 2950
Website www.athenex.com
FullTime employees 652
Industry Drug Manufacturers—Specialty & Generic
Sector Healthcare
Exchange XNAS
Ticker ATNX
Market www.nasdaq.com

Athenex Inc ESG Scores

Environment scores

Environment ESG Factors Scores
Environment Score 0
Peer Environment Performance unknown
Environment Percentile unknown
Palm Oil unknown
Nuclear unknown
Fur Leather unknown
GMO unknown
Coal unknown
Pesticides unknown
Animal Testing unknown

Social scores

Social ESG Factors Scores
Social Score 0
Peer Social Performance unknown
Social Percentile unknown
Highest Controversy unknown
Peer Highest Controversy Performance unknown
Adult unknown
Gambling unknown
Alcoholic unknown
Tobacco unknown
Catholic unknown
Controversial Weapons unknown
Small Arms unknown
Military Contract unknown
Peer Count unknown

Related Controversy:


Governance scores

Governance ESG Factors Scores
Governance Score 0
Peer Governance Performance unknown
Governance Percentile unknown

ESG at glance
Total ESG Scores: unknown
Environment Score: 0
Social Score: 0
Governance Score: 0

ESG Performance: unknown

Peer Group: unknown

Peer Esg Score Performance: unknown

Rating Year: unknown

Rating Month: unknown

Max Age: unknown

Percentile: unknown